|
DaihanPharm is a pharmaceutical manufacturer specializing in the production and sale of basic medicines and nutritional solutions. The company's core business involves manufacturing intravenous fluids, ampoules, and non-oral nutritional supplements for hospitals and clinics. It also operates in the over-the-counter (OTC) sector, producing lens cleaning solutions and sodium chloride solutions for general consumers. The company serves a domestic market that includes general hospitals, clinics, and pharmacies, while also pursuing export opportunities in Southeast Asian countries. Its production facilities include automated manufacturing lines and warehouses designed to ensure stable supply and quality control. DaihanPharm engages in contract manufacturing (CMO) services and maintains a sales network through medical representatives and distribution partners. The company focuses on essential therapeutic products and continues to develop new formulations, including intravenous lipid emulsions and total nutrient admixtures. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage daihan.com |
| Sector Healthcare | IR page — | |
|
Tags
intravenous fluids, nutritional supplements, ampoules, otc products, pharmaceutical manufacturing, contract manufacturing, essential medicines
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 149.85B |
| P/E | 5.44 |
| P/BV | 0.49 |
| P/S | 0.69 |
| P/OCF | 4.01 |
| P/FCF | 7.43 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 9.6% |
| ROI | 9.2% |
| ROIC | 8.7% |
| Profit margin | 13.3% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | Yes |
| Revenue up 5y | Yes |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | 58.8% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 208.614B | 204.195B | 195.911B | 184.268B | 171.463B | 166.08B | 168.762B | 158.72B | 144.439B | 139.437B | 124.276B | 111.709B | 106.803B |
| Free cash flow | 481.53M | 19.841B | — | 20.378B | — | 28.267B | 17.959B | -1.748B | -592.245M | — | — | — | — |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpPrompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.